Osteogenesis Imperfecta and Low Bone Density Gene Mutation Panel, NGS
Osteogenesis imperfecta (OI) is a genetic condition characterized by defective synthesis of type I collagen, leading to poor integrity of the bone's organic matter, resulting in skeletal deformities, decreased bone density, and fragile bones. This condition is also known as "brittle bone disease." Individuals with OI may present with one or more symptoms, including frequent fractures, brittle teeth, blue/grey sclera, short stature, and deafness. Clinically, OI is subdivided into five types: non-deforming, perinatal, progressively deforming, moderate, and calcification type. OI affects 1 in 15,000 to 20,000 individuals. Approximately 90% of OI cases result from gene mutations, predominantly in the COL1A1 and COL1A2 genes. These genes encode the pro α1 and pro α2 chains of type I collagen, and mutations can lead to defective type I collagen synthesis.
To date, over 1,500 mutations in the COL1A1 and COL1A2 genes have been identified, leading to either structural or quantitative defects in type I collagen. Structural defects result in severe forms of bone fragility compared to quantitative defects. While COL1A1 and COL1A2 gene mutations are responsible for 90% of OI cases, several other genes also contribute to the disease's development. The Osteogenesis Imperfecta and Low Bone Density Gene Mutation Panel utilizes next-generation sequencing to investigate sequence variations in 25 genes associated with bone density disorders. These genes include ALPL, ANO5, BMP1, COL1A1, COL1A2, CREB3L1, CRTAP, FKBP10, IFITM5, LRP5, MBTPS2, P3H1, P4HB, PLOD2, PLS3, PPIB, SEC24D, SERPINF1, SERPINH1, SP7, SPARC, TAPT1, TMEM38B, WNT1, and XYLT2. The testing aids in distinguishing OI from congenital hypophosphatasia, achondroplasia, and osteopenia of leukemia.
- Aid in the diagnosis of osteogenesis imperfecta and other hereditary conditions associated with bone fragility
- Providing a genetic evaluation for patients with a personal or family history suggestive osteogenesis imperfecta and other hereditary conditions associated with bone fragility
Mutations in the tested genes suggest osteogenesis imperfecta or compromised type I collagen synthesis and stability.
For example, COL1A1 c.174C>A (p.Cys58*): The heterozygous c.174C>A (p.Cys58*) variant in the COL1A1 gene (MIM: 120150) is classified as pathogenic. The COL1A1 gene encodes the alpha 1chain of type I collagen, which is one of the major types of collagens in skin, tendon, and bone.
Pathogenic variants in COL1A1 are associated with several different autosomal dominant disorders, including osteogenesis imperfecta (OI), Caffey disease, arthrochalasia Ehlers-Danlos syndrome (also known as aEDS or EDS type VIIA), and COL1A1-related classical EDS.
Negative, no reportable variants were detected
Conventional sequencing, Next-generation sequencing (NGS).
Whole blood (EDTA) or amniotic fluid.
Stability
- Ambient: 72 hours
- Refrigerated: 14 days
- Frozen: 28 days
- Curr Opin Pediatr. 2019 Dec;31(6):708-715. [PMID: 31693577]
- Medicina (Kaunas). 2021 May 10;57(5):464. [PMID: 34068551]
- Lancet. 2004 Apr 24;363(9418):1377-85. [PMID: 15110498]
- Clin Genet. 2020 Mar;97(3):396-406. [PMID: 31794058]
- Biosci Rep. 2019 Jul 25;39(7) BSR20181409. [PMID: 31239369]